Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
08 Fevereiro 2024 - 10:00AM
Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that
is reimagining therapeutic delivery, today announced it will
participate in the Inflammatory Bowel Disease Symposium hosted
virtually by Canaccord Genuity Capital Markets on Wednesday,
February 28, 2024.
Ariella Kelman, M.D., Chief Medical Officer, will
participate in the panel titled “The Next Evolutionary Steps in
Addressing IBD,” beginning at 10:00 AM Eastern / 7:00 AM Pacific
time.
Interested parties may contact their Canaccord
Genuity representative to request registration details for the
virtual event.
About Biora TherapeuticsBiora
Therapeutics is reimagining therapeutic delivery. By creating
innovative smart pills designed for targeted drug delivery to the
GI tract, and systemic, needle-free delivery of biotherapeutics,
the company is developing therapies to improve patients’ lives.
Biora is focused on development of two therapeutics
platforms: the clinical-stage NaviCap™ targeted oral delivery
platform, which is designed to improve outcomes for patients with
inflammatory bowel disease through treatment at the site of disease
in the gastrointestinal tract, and the preclinical-stage BioJet™
systemic oral delivery platform, which is designed to replace
injection for better management of chronic diseases through
needle-free, oral delivery of large molecules.
For more information, visit bioratherapeutics.com
or follow the company on LinkedIn or Twitter.
Safe Harbor Statement or Forward-Looking
StatementsThis press release contains “forward-looking
statements” within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995, which
statements are subject to substantial risks and uncertainties and
are based on estimates and assumptions. All statements, other than
statements of historical facts included in this press release,
including statements concerning our anticipated milestones, the
progress and future expectations and goals of our research and
development and clinical efforts and research collaboration plans
and expectations are forward-looking statements. In some cases, you
can identify forward-looking statements by terms such as
“anticipate,” “may,” “might,” “will,” “objective,” “intend,”
“should,” “could,” “can,” “would,” “expect,” “believe,” “design,”
“estimate,” “predict,” “potential,” “plan,” “target,” or the
negative of these terms, and similar expressions intended to
identify forward-looking statements. These statements reflect our
plans, estimates, and expectations, as of the date of this press
release. These statements involve known and unknown risks,
uncertainties and other factors that could cause our actual results
to differ materially from the forward-looking statements expressed
or implied in this press release. Such risks, uncertainties, and
other factors include, among others, our ability to innovate in the
field of therapeutics, our ability to make future filings and
initiate clinical trials on expected timelines or at all, our
ability to obtain and maintain regulatory approval, clearance, or
acceptance of our clinical trials or products on expected timelines
or at all, our plans to research, develop, and commercialize new
products, the unpredictable relationship between preclinical study
results and clinical study results, our expectations regarding
allowed patents or intended grants to result in issued or granted
patents, our expectations regarding opportunities with current or
future pharmaceutical collaborators, our ability to raise
sufficient capital to achieve our business objectives, and those
risks described in “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” in our
Annual Report on Form 10-K for the year ended December 31, 2022
filed with the SEC and other subsequent documents, including
Quarterly Reports, that we file with the SEC.
Biora Therapeutics expressly disclaims any
obligation to update any forward-looking statements whether as a
result of new information, future events or otherwise, except as
required by law.
Investor ContactChuck
PadalaManaging Director, LifeSci
AdvisorsIR@bioratherapeutics.com(646) 627-8390
Media
Contactmedia@bioratherapeutics.com
Biora Therapeutics (NASDAQ:BIOR)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Biora Therapeutics (NASDAQ:BIOR)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024